D
DBI
vs
D
DAX Index
Over the past 12 months, DBI has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +11% growth.
Stocks Performance
DBI vs DAX Index
Performance Gap
DBI vs DAX Index
Performance By Year
DBI vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Deutsche Biotech Innovativ AG
Glance View
Deutsche Biotech Innovativ AG invests in biotechnology companies that focus on research and development, as well as development of clinical drug agents for vascular integrity improvement, solid tumors, and antibody-based therapy for the treatment of organ failure in patients with cardiogenic shock. The company is headquartered in Hennigsdorf, Brandenburg and currently employs 0 full-time employees. The company went IPO on 2012-04-05. The firm focuses on the identification of relevant biomarkers in the blood of affected patients, and also develops targeted therapies to prevent septic shock and inhibit tumor growth, as well as a small molecule drug for breast cancer prevention. . Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest. The firm's subsidiaries include AngioBiomed GmbH, AdrenoMed AG, Oncoprevent GmbH and MyLife Diagnostics GmbH.
